NNovo Nordisk Read More Novo Nordisk’s Semaglutide Data Piles Up, Yet Stock Remains Unmoved2026-06-08 Novo Nordisk reveals new semaglutide data at ADA, including longevity and aesthetic potential, but shares remain under pressure—down…